NSF International purchases majority stake in Amarex CRO

This article was originally published here

The acquisition of Amarex will help NSF to expand its consulting services to the medical device and pharma/biotech industries. Amarex will be included in NSF’s global health science

The post NSF International purchases majority stake in Amarex CRO appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply